Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions

doi:10.3748/wjg.v23.i32.5875

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 32

This Article

(323)

(445)

(0)

(14086)

(85)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Minireviews

World J Gastroenterol. Aug 28, 2017; 23(32): 5875-5886
Published online Aug 28, 2017. doi: 10.3748/wjg.v23.i32.5875

Table 2 Principal clinical trials with nab-paclitaxel in metastatic pancreatic cancer

Study ID	Setting	Study drugs	Phase	Status
NCT02993731	Metastatic	Nab-paclitaxel + Gemcitabine +/-Napabucasin	III	Recruiting
NCT02101021	Metastatic	Nab-paclitaxel + Gemcitabine +/- Momelotinib	III	Active not recruiting
NCT02715804	Metastatic	Nab-paclitaxel + Gemcitabine +/-PEGPH20	III	Recruiting
NCT02436668	Metastatic	Nab-paclitaxel + Gemcitabine +/- Ibrutinib	II-III	Recruiting
NCT02827201	Metastatic	Sequential Nab-paclitaxel + Gemcitabine /FOLFIRI	II	Active not recruiting
NCT02767557	Metastatic	Nab-paclitaxel + Gemcitabine +/-tocilizumab	II	Recruiting
NCT03086369	Metastatic	Nab-paclitaxel + Gemcitabine +/- Olaratumab	II	Not yet recruiting
NCT02879318	Metastatic	Nab-paclitaxel + Gemcitabine +/- Durvalumab + Tremelimumab	II	Recruiting
NCT02399137	Metastatic	Nab-paclitaxel + Gemcitabine +	II	Recruiting
NCT02399137	Metastatic	MM-141	II	Recruiting
NCT02340117	Metastatic	Nab-paclitaxel + Gemcitabine +	II	Recruiting
NCT02340117	Metastatic	SGT-53	II	Recruiting
NCT02124317	Metastatic	Nab-paclitaxel + S-1	II	Active not recruiting
NCT03076216	Metastatic	Nab-paclitaxel + Gemcitabine + ONCOsil	II	Not yet recruiting
NCT02905578	Metastatic	Nab-paclitaxel + Gemcitabine +	II	Not yet recruiting
NCT02905578	Metastatic	High-dose ascorbate	II	Not yet recruiting
NCT02732938	Metastatic	Nab-paclitaxel + Gemcitabine + PF-04136309	II	Recruiting
NCT02551991	Metastatic	Nal-Iri or Gemcitabine +	II	Recruiting
NCT02551991	Metastatic	Nab-paclitaxel	II	Recruiting
NCT03009058	Metastatic	Nab-paclitaxel + Gemcitabine +	I-II	Not yet recruiting
NCT03009058	Metastatic	IMM 101	I-II	Not yet recruiting
NCT02559674	Metastatic	Nab-paclitaxel + Gemcitabine +	I-II	Recruiting
NCT02559674	Metastatic	ALT-803	I-II	Recruiting
NCT02705196	Metastatic	Nab-paclitaxel + Gemcitabine + LOAd703 oncolytic virus	I-II	Recruiting
NCT01834235	Metastatic	Nab-paclitaxel + Gemcitabine +	I-II	Active not recruiting
NCT01834235	Metastatic	NPC-1C	I-II	Active not recruiting
NCT01730222	Metastatic	Nab-paclitaxel + Gemcitabine + Capecitabine + Cisplatin	I-II	Recruiting
NCT02620800	Metastatic	Nab-paclitaxel + 5-fluorouracil + Leucovorin + Bevacizumab + Oxaliplatin	I-II	Recruiting
NCT01506973	Metastatic	Nab-paclitaxel + Gemcitabine + Hydroxychloroquine	I-II	Recruiting
NCT02504333	Metastatic	Nab-paclitaxel + Gemcitabine followed by FOLFOX	I-II	Recruiting
NCT02050178	Metastatic	Nab-paclitaxel + Gemcitabine + OMP-54F28	I	Active not recruiting
NCT02309177	Metastatic	Nab-paclitaxel + Nivolumab +/- Gemcitabine	I	Recruiting
NCT02514031	Metastatic	Nab-paclitaxel + Gemcitabine +	I	Recruiting
NCT02514031	Metastatic	ARQ-761	I	Recruiting
NCT01934634	Metastatic	Nab-paclitaxel + Gemcitabine + LCL161	I	Active not recruiting
NCT02101580	Metastatic	Nab-paclitaxel + Gemcitabine +	I	Active not recruiting
NCT02101580	Metastatic	ADI-PEG 20	I	Active not recruiting
NCT02138383	Metastatic	Nab-paclitaxel + Gemcitabine + Enzalutamide	I	Active not recruiting
NCT02975141	Metastatic	Nab-paclitaxel + Gemcitabine + Afatinib	I	Recruiting
NCT02227940	Metastatic	Nab-paclitaxel + Gemcitabine + Ceritinib	I	Recruiting
NCT02231723	Metastatic	Nab-paclitaxel + Gemcitabine +	I	Recruiting
NCT02231723	Metastatic	BBI608	I	Recruiting
NCT02501902	Metastatic	Nab-paclitaxel + Palbociclib	I	Recruiting

Nal-Iri: Nanoliposomal irinotecan.

Full Size Table

Citation: Giordano G, Pancione M, Olivieri N, Parcesepe P, Velocci M, Di Raimo T, Coppola L, Toffoli G, D’Andrea MR. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions. World J Gastroenterol 2017; 23(32): 5875-5886
URL: https://www.wjgnet.com/1007-9327/full/v23/i32/5875.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i32.5875

Giordano G, Pancione M, Olivieri N, Parcesepe P, Velocci M, Di Raimo T, Coppola L, Toffoli G, D’Andrea MR. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions. World J Gastroenterol 2017; 23(32): 5875-5886 [PMID: 28932079 DOI: 10.3748/wjg.v23.i32.5875]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.